Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New wearable pump could send heart failure patients home early

NCT ID NCT05419115

Symptom relief Sponsor: NHS Greater Glasgow and Clyde Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether a new wearable pump that delivers a water pill (furosemide) under the skin could help heart failure patients leave the hospital earlier. 172 adults admitted for heart failure were randomly assigned to either go home with the pump or stay in the hospital for standard IV treatment. The main goal was to see if the home group spent more days alive and out of the hospital within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
furosemide (a water pill) given under the skin via a wearable pump
What this could lead to
If it works, this could allow heart failure patients to finish their treatment at home instead of in the hospital, improving comfort and freeing up hospital beds.
What could go wrong
This is a small, early-phase trial (172 people) testing a new device and drug formulation. The device is not yet approved, and the approach may not prove safe or effective enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

172 people

The number who actually took part.

Started

Nov 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * Male or female ≥18 years of age * Meet European Society of Cardiology (ESC) criteria for diagnosis of HF1 * Elevated natriuretic peptide (BNP\> 100 pg/mL or NTproBNP \>300 pg/mL) * Signs and symptoms of HF * Echocardiographic structural or functional abnormality according to ESC guidelines * Have received IV diuretic for treatment of HF within preceding 24 hours * Be less than 96 hours after admission to hospital * Requiring IV diuretics for a minimum of 24 hours after screening * Have an echocardiogram or other assessment of cardiac structure and function within preceding 12 months or at screening * Have a home environment that allows the patient to be able to mobilise within their residence and be able to pass urine into their toilet (unless catheterised) * Able to operate (or has a caregiver who can operate) SQIN-Infusor (as assessed by training on a dummy device at screening) Exclusion Criteria: * Unable to consent due to significant cognitive impairment or lack of capacity * Unable to operate SQIN-Infusor (or no caregiver who is able to operate the device) * Geographical reasons preventing follow-up visits * Pregnancy or breast-feeding * Requiring treatment with IV furosemide \>250 mg furosemide per day in the opinion of the treating physician * Left sided valve disease with planned surgery or percutaneous intervention * Type 1 myocardial infarction during index hospitalisation (participants with type 2 myocardial infarction can be included)2 * Renal impairment, defined as estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73 m 2 at screening * Reasons (other than HF) which may prevent discharge from hospital, such as social circumstances or other significant medical condition (at investigator discretion) * Women of childbearing potential * Patient on active cardiac transplant waiting list * Patient requiring on-going inotropic, vasopressor or intraaortic balloon pump support * Potassium \<3.0 mmol/L * Potassium \>6.0 mmol/L * Sodium \<125 mmol/L * Any surgical or medical condition which, in the opinion of the investigator, may pose an undue risk to the subject, interfere with participation in the study or which may affect the integrity of the data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Basildon University Hospital

    Basildon, England, SS16 5NL, United Kingdom

  • Blackpool Victoria Hospital

    Blackpool, England, FY3 8NR, United Kingdom

  • Forth Valley Hospital

    Larbert, Scotland, FK5 4WR, United Kingdom

  • Glasgow Royal Infirmary

    Glasgow, Scotland, G12 8TA, United Kingdom

  • Glenfield Hospital

    Leicester, England, LE3 9QP, United Kingdom

  • Leeds General Infirmary

    Leeds, England, LS1 3EX, United Kingdom

  • Manchester Heart Centre

    Manchester, England, M13 9WL, United Kingdom

  • Ninewells Hospital

    Dundee, Scotland, DD1 9SY, United Kingdom

  • Queen Alexandra Hospital

    Portsmouth, England, PO6 3LY, United Kingdom

  • Queen Elizabeth University Hospital

    Glasgow, Strathclyde, G51 4TF, United Kingdom

  • Southmead Hospital

    Bristol, England, BS10 5NB, United Kingdom

  • St Thomas' Hospital

    London, England, SE1 7EH, United Kingdom

  • St. George's University of London

    London, England, SW17 0RE, United Kingdom

  • Stoke Mandeville Hospital

    Aylesbury, England, HP21 8AL, United Kingdom

  • Sunderland Royal Hospital

    Sunderland, England, SR4 7TP, United Kingdom

  • The Great Western Hospital

    Swindon, United Kingdom, SN3 6BB, United Kingdom

  • University Hospital Ayr

    Ayr, Scotland, KA6 6DX, United Kingdom

  • University Hospital Monklands

    Airdrie, ML6 0JS, United Kingdom

  • University Hospital Southampton

    Southampton, United Kingdom

  • University Hospital of North Tees

    Hardwick, England, TS19 8PE, United Kingdom

  • University Hospitals Dorset

    Bournemouth, England, BH7 7DW, United Kingdom

  • Wycombe General Hospital

    High Wycombe, England, HP11 2TT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.